This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DOW-COLORCON Controlled Release Alliance Launches METHOCEL™ DC2 To Help Reduce Development Time And Lower Manufacturing Costs At The 2013 AAPS Annual Meeting And Expo

Dow Pharma & Food Solutions, a business unit of The Dow Chemical Company (NYSE: DOW) and Colorcon Inc., will present the next-generation METHOCEL™ DC2 polymer at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Expo in San Antonio, Texas from November 10 to 14, 2013. Designed to help the pharmaceutical industry shorten development time and lower manufacturing costs, the DOW-COLORCON Controlled Release Alliance supports pharmaceutical manufactures looking to switch to roller compaction and direct compression for matrix tablet applications.

“Our customers count on us to continually develop customized solutions to address their needs, help them remain competitive and support their growth,” said Dago Caceres, marketing leader, Dow Pharma & Food Solutions. “Our innovative solutions for tablet production will help drug companies save time and money,” he added.

Exceptional flow properties help lower manufacturing cost by up to 60 percent

METHOCEL DC2 will help manufacturers replace wet granulation in matrix tablet production, lowering manufacturing costs by as much as 60 percent, reducing waste, and shortening development time. Furthermore, direct compression methods offer better formulation options for heat- and moisture-sensitive active pharmaceutical ingredients (APIs).

Spheroidal particles and fewer fines

METHOCEL™ DC2 polymers deliver exceptional flow properties and process capability, as well as consistent modified-release performance for matrix formulations. They maintain the same viscosities, degrees of methoxyl and hydroxypropyl substitution, and other important properties of their CR grade equivalents while optimizing processability.

“Compared to METHOCEL™ CR, next generation METHOCEL™ DC2 notably improves the flow properties of powder blends, facilitating roller compaction and direct compression. Differences in morphology drive the improved flow,” explains Dr. True Rogers, technologies leader for Dow Pharma & Food Solutions. “Regarding processability, METHOCEL™ DC2 produces tablets exhibiting higher reproducibility in weight and hardness as well as more accurate and precise API content uniformity from tablet-to-tablet.”

A portfolio that meets US, European and Japanese pharmacopoeia specifications

Three direct compression grades of METHOCEL™ DC2 are now available: K100 LV, K4M and K100M, each chemically identical to current METHOCEL™ Premium products meeting the harmonized monograph specifications.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,282.20 -3.54 -0.02%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs